CureVac Scales Up EU Manufacturing Capabilities for COVID-19 Vaccine
German drugmaker CureVac said it is scaling up its EU manufacturing capability and plans to ship 300 million doses of its COVID-19 vaccine, CVnCoV, across the world next year and 600 million doses in 2022.
The company has also entered into an agreement with the European Commission to supply 225 million doses with the option for an additional 180 million doses.
One advantage of CureVac’s messenger RNA-based vaccine is that it can remain stable for at least three months at 41 degrees Fahrenheit (5 degrees Celsius), which makes it easier to distribute than competitor vaccines that must be stored at ultra-cold temperatures.
The company hopes to begin a phase 3 clinical trial of CVnCoV by year’s end.